NEWTON, Mass., July 7, 2026
Acumen Pharmaceuticals announced that it will present three scientific studies at the Alzheimer’s Association International Conference (AAIC®) 2026, taking place in London from July 12–15, 2026. The presentations include one oral session and two poster presentations highlighting the company’s Enhanced Brain Delivery™ (EBD™) technology collaboration with JCR Pharmaceuticals, along with new patient-centered research from its ongoing ALTITUDE-AD Phase 2 clinical trial evaluating sabirnetug (ACU193) in early Alzheimer’s disease.
Enhanced Brain Delivery Technology Demonstrates Progress in Preclinical Research
A key highlight of Acumen’s AAIC presentations is new preclinical research evaluating bispecific antibodies that selectively target soluble amyloid beta oligomers (AβOs) while utilizing transferrin receptor-mediated transport to improve delivery across the blood-brain barrier. Developed through Acumen’s collaboration with JCR Pharmaceuticals, the Enhanced Brain Delivery platform combines Acumen’s AβO-selective antibody expertise with JCR’s proprietary J-Brain Cargo® technology to improve therapeutic concentrations within the brain. The company believes this strategy could enhance treatment effectiveness while potentially improving the safety profile of future Alzheimer’s therapies.
ALTITUDE-AD Research Highlights the Patient Perspective in Early Alzheimer’s Disease
Acumen will also present findings from the ALTITUDE-AD study population that examine patient experiences during the early symptomatic stages of Alzheimer’s disease. The research is designed to provide a deeper understanding of cognitive, functional, and psychosocial challenges faced by patients, generating insights that may help guide future clinical trial design and therapeutic development. The company views patient-centered research as an important component of developing treatments that address meaningful clinical outcomes for individuals living with Alzheimer’s disease.
Advertisement
Sabirnetug Continues to Advance in Phase 2 Development
Acumen’s lead investigational therapy, sabirnetug (ACU193), is a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers, which are believed to play a central role in the early progression of Alzheimer’s disease. The therapy has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is currently being evaluated in the ALTITUDE-AD Phase 2 trial, a randomized, double-blind, placebo-controlled study involving 542 participants with early Alzheimer’s disease across the United States, Canada, the European Union, and the United Kingdom. Topline data from the study are expected in late 2026.
In parallel, Acumen is expanding its Alzheimer’s development strategy by investigating a subcutaneous formulation of sabirnetug using Halozyme’s ENHANZE® drug delivery technology while continuing to advance its collaboration with JCR Pharmaceuticals to develop next-generation Alzheimer’s therapies capable of achieving improved penetration across the blood-brain barrier. The presentations at AAIC 2026 are expected to provide additional scientific validation for both Acumen’s clinical program and its emerging Enhanced Brain Delivery platform.
Source: Acumen Pharmaceuticals press release
